NURITAS
Nuritas , a biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides, has closed a $45 million USD Series B funding round. The investment, led by Chicago-based Cleveland Avenue, LLC , includes Grosvenor’s Wheatsheaf Group , the European Circular Bioeconomy Fund (ECBF ), Singapore-based Vertex Holdings , Nutresa Ventures / Veronorte and CJ . Cultivian Sandbox Ventures and VisVires New Protein , who led previous rounds, also participated. Other early investors include U2’s Bono and The Edge, Salesforce CEO Marc Benioff and Ali Partovi. Total funding to date is $75 million USD.
The new funding will accelerate Nuritas’ global expansion and support its mission to unlock the power of nature to make many of the products we consume daily healthier, safer and more sustainable. Randall Lewis, managing director of Cleveland Avenue, LLC and Stephan Dolezalek, executive director of Grosvenor’s Wheatsheaf Group will join Nuritas’ Board of Directors.
Nuritas has also grown its Advisory Board with Indra Nooyi, former CEO of Pepsico and board member at Amazon, Joerg Ohle of Bayer’s Global Consumer Health division, and Bruce German, professor and chemist of food science and technology at the University of California, Davis and the director of its Foods for Health Institute.
“It has been a landmark year, resulting in the expansion of our peptide portfolio, growing the commercial team and developing key global partnerships,” said Dr. Nora Khaldi, founder and CEO of Nuritas. “Our new investors bring a wealth of invaluable expertise, and this latest round will help to build our US headquarters, continue to expand our team, scale our platform to discover more life-changing ingredients and accelerate our route to market.”
Nuritas has established the world’s largest peptide knowledge base. Peptides are smaller versions of proteins with the same nutritional power, but with added highly specific benefits. Many of these are highly valuable to humans but have not yet been harnessed for their full potential. Nuritas uses a proprietary AI and genomics platform called Nπϕ™ (Nuritas Peptide Finder) to rapidly analyze billions of hidden peptides in plants and natural food sources to predict and identify how they impact specific health areas, molecular pathways or receptors. The Nuritas platform has been shown to identify and develop new bioactives 10 times faster and with much greater accuracy than traditional discovery methods, significantly reducing costs.
“Nuritas is led by a talented team and its AI-powered, peptide discovery platform Nπϕ is a novel and proprietary platform technology that offers unprecedented value to the future of our health and our planet,” said Lewis. ”Cleveland Avenue is pleased to be a part of the company’s ongoing growth and we anticipate Nuritas will become a global ingredient powerhouse and a partner of choice for companies around the world.”
Nπϕ has attracted high-profile partnerships and customers, including Nestle, Mars, Sumitomo Corporation and Pharmavite. The company’s science-proven bioactive peptides are unlocked from plants and natural food sources, with applications across functional foods, supplements, medical food, cosmetics and food technology.
Stephan Dolezalek, executive director, Grosvernor’s Wheatsheaf Group, said: “We are pleased to join Nuritas as it prepares to launch new consumer products alongside an impressive pipeline of novel molecules and ongoing partnerships with global consumer product businesses. Nuritas’ capabilities match Wheatsheaf’s mission to re-shape how food is produced and consumed while benefiting the environment and human health.”
Nuritas introduced PeptAide™ 4 , the world’s first AI-discovered ingredient in rice (together with BASF) and recently launched two clinically proven ingredients: PeptiYouth™ , discovered from peas and supporting skin health, and PeptiStrong™ , discovered in fava-beans and supporting muscle health. Both are being formulated for early 2022 market entry.
About Cleveland Avenue, LLC
Founded by Don Thompson, the former President and CEO of McDonald’s Corporation, Cleveland Avenue is a venture capital firm that invests in food and beverage brands, and technology companies that positively disrupt large and growing markets. Learn more about Cleveland Avenue at clevelandavenue.com and follow us on Twitter , LinkedIn , and Instagram .
About Nuritas
Nuritas is revolutionizing the discovery of novel, natural and scientifically proven bioactive ingredients that enable their partners to create better or new product solutions for their customers. The company’s disruptive computational approach to discovery uses artificial intelligence, deep learning, and genomics to rapidly and efficiently predict and then unlock the most health-benefiting components hidden within plants and natural food sources, called peptides. Nuritas has since established the world’s largest peptide knowledge base. Through its discoveries, Nuritas wants to firstly manage and improve human health and secondly help make our food system more sustainable by replacing current unwanted ingredients and molecules with more natural and sustainable ones. Find us on Twitter , LinkedIn or via our website at www.nuritas.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005401/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 16:00:00 CET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
BitGo Holdings annoncerer lancering af børsintroduktion14.1.2026 15:53:00 CET | Pressemeddelelse
BitGo Holdings, Inc. ("BitGo"), som er en virksomhed inden for digital infrastruktur til aktiver, annoncerede i dag lanceringen af sin børsintroduktion af 11.821.595 aktier af klasse A-stamaktier i henhold til en registreringserklæring på formular S-1, der er indsendt til det amerikanske finanstilsyn, U.S. Securities and Exchange Commission (kendt som "SEC"). Udbuddet omfatter 11.000.000 aktier af klasse A-stamaktier udbudt af BitGo samt 821.595 aktier af klasse A-stamaktier udbudt af visse eksisterende aktionærer i BitGo. BitGo vil ikke modtage noget provenu fra salget af aktier fra de sælgende aktionærer i forbindelse med udbuddet. I forbindelse med udbuddet har BitGo til hensigt at give konsortiet af garantibanker en 30-dages option til at købe op til yderligere 1.770.000 aktier af klasse A-stamaktier. Den forventede introduktionskurs i forbindelse med børsnoteringen vil ligge mellem 15 og 17 USD pr. aktie. BitGo har ansøgt om at få sine klasse A-stamaktier optaget til handel på New
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
